Madrigal Pharmaceuticals Inc stock is traded at $427.39, with a volume of 441,234. It is up +0.51% in the last 24 hours and down -5.47% over the past month. Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Previous Close:
$425.21
Open:
$424.92
24h Volume:
441,234
Relative Volume:
0.50
Market Cap:
$9.93B
Revenue:
$1.13B
Net Income/Loss:
-$309.44M
P/E Ratio:
-
EPS:
-$12.80
Net Cash Flow:
-$275.41M
1W Performance:
+6.95%
1M Performance:
-5.47%
6M Performance:
-17.63%
1Y Performance:
-17.00%
1-Day Range:
$414.16$428.90
1-Week Range:
$402.00$443.30
52-Week Range:
$353.54$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
404-380-9263Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS